Turkish Journal of Medical Sciences




To investigate the memory-enhancing drugs piracetam, vinpocetine, and ginkgo biloba for their ability to reduce catalepsy in mice treated with haloperidol. Haloperidol is a classic neuroleptic drug that induces motor abnormalities and cognitive impairment due to a blockade of dopamine D2 receptors in the striatum. Materials and methods: Catalepsy was induced by intraperitoneal haloperidol (2 mg/kg) administration. The drugs being tested were either administered intraperitoneally (IP) along with the dosage of haloperidol or 30 min prior to the introduction of the haloperidol. Catalepsy was measured using the bar test. Results: The administration of haloperidol (2 mg/kg, IP) resulted in significant catalepsy. Piracetam (in dosages of 50, 100, and 300 mg/kg) given IP at the time of haloperidol administration reduced the duration of catalepsy by 24.4%, 32.3%, and 48.2%, respectively. Piracetam given as a 30-min pretreatment reduced the duration of catalepsy by 59.5%, 72.3%, and 78.2%, respectively. Vinpocetine coadministered IP with haloperidol did not modify catalepsy, but given as a 30-min pretreatment, the drug increased catalepsy duration by 53.5%, 53.6%, and 65.1%, respectively. Ginkgo biloba coadministered IP with haloperidol at 25, 50, or 150 mg/kg increased catalepsy duration by 13.6%-17.1%. Ginkgo biloba given 30 min prior to haloperidol increased catalepsy duration by 29.1%, 35.1%, and 37.2%, respectively. Conclusion: The present study indicates that the nootropic drug piracetam reduces haloperidol-induced catalepsy in mice.


Catalepsy, haloperidol, piracetam, vinpocetine, ginkgo biloba, mice

First Page


Last Page